ArticleBritish journal of cancer2009
Management of chemotherapy-associated febrile neutropenia.
Article in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 53 citations in OpenAlex.
- Effect of Channa striata Extract Supplementation on Febrile Neutropenia in Acute Myeloid Leukemia Patients Undergoing Chemotherapy: A Randomized Controlled Study.Asian Pacific journal of cancer prevention : APJCP · 2024Trial
- Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.Cancer chemotherapy and pharmacology · 2021Trial
- Prolonging the Lifespan of Neutrophils for Granulocyte Transfusion in Neutropenic Mice with Bacterial Pneumonia.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Anorectal Infections in Neutropenic Leukemia Patients: A Common Clinical Challenge.Journal of hematology · 2024Review
- Effectiveness of Extended or Continuous vs. Bolus Infusion of Broad-Spectrum Beta-Lactam Antibiotics for Febrile Neutropenia: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2023Review
- Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.Cancer medicine · 2020Article
- Holistic Nursing Upon the Knowledge on Care During Myelosuppression among Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Assessment of Patients' Knowledge in Managing Side Effects of Chemotherapy: Case of King Abdul-Aziz University Hospital.Journal of cancer education : the official journal of the American Association for Cancer Education · 2020Article
- Appraising of the Clinical Practice Guidelines Quality in the Non-Pharmacological Management of Chemotherapy-Induced Febrile Neutropenia; A ReviewAsian Pacific journal of cancer prevention : APJCP · 2018Review
- Monitoring Neutropenia for Cancer Patients at the Point of Care.Small methods · 2017Article
- Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.Advances in therapy · 2016Article
- Individual level covariate adjusted conditional autoregressive (indiCAR) model for disease mapping.International journal of health geographics · 2016Article
- Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Observational
- Model-based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment.Pharmaceutical research · 2015Article
- Factors associated with hospital length of stay among cancer patients with febrile neutropenia.PloS one · 2014Article
- Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.Pharmaceutical research · 2013Article
- Communicating safe outpatient management of fever and neutropenia.Journal of oncology practice · 2013Article
- Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.British journal of cancer · 2012Article
- Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2011Article
- Fulminate anaerobic bacteremia after chemotherapy for metastatic breast cancer despite the prophylactic use of GCSF.International medical case reports journal · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of febrile neutropenia during a course of chemotherapy is not only a life-threatening complication, it can also lead to a decision to reduce chemotherapy intensity in subsequent treatment cycles, thus putting patient outcomes at risk. Although there are strategies available for the primary prevention of febrile neutropenia, these are not widely used in the UK management of breast cancer. It is, therefore, paramount to have a well thought out and rigorously implemented care protocol for febrile neutropenia, involving patients, family/carers and health-care professionals in both primary and secondary care, to ensure early detection and effective management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.